Dr. John Howard Sampson, M.D., Ph.D, M.B.A, M.H.S.c
Dr. Sampson is a recognized leader in the surgical resection and experimental treatment of complex brain tumors. His clinical practice is focused on treating patients with both benign and malignant brain tumors, while his research laboratory is actively investigating new modalities of direct brain tumor infusion and immunotherapy. His research led to the development of a vaccine against a common mutation in brain tumors, which has been given Breakthrough Therapy Designation by the FDA after it was shown to extend survival in patients with glioblastoma multiforme (GBM), the most malignant form of brain cancer. He has authored more than 240 peer-reviewed publications in this field and has been continuously funded by the NIH since 2000.